Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine. (AcNT-COVID19)

Clinical Trial ID NCT04596098

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04596098

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009 17.14
2 Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 11.07
3 Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009 1.47
4 Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 2006 1.08
5 Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity 2016 0.90
6 Antibody Response and Disease Severity in Healthcare Worker MERS Survivors. Emerg Infect Dis 2016 0.87
7 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020 0.75
Next 100